Sandia Labs technology used in Fukushima cleanup
"It's the kind of thing that sends a chill," said Mark Rigali, manager of the geochemistry group at Sandia. "We've helped really make a difference in the world. These are the kinds of successes we want to see with all our intellectual property."
UOP LLC, a Honeywell company, late last year renegotiated its license of the Sandia technology being used at Fukushima. The revised license makes UOP the exclusive U.S. manufacturer of crystalline silico-titanate, or CST, a molecular sieve that can separate highly volatile elements from radioactive wastewater.
"Sandia has a very important and longstanding business relationship with UOP," said Bianca Thayer of Sandia's Intellectual Property Management, Alliances and Licensing Department. "This is an opportunity to grow our partnership with the company."
The late Sandia chemist Bob Dosch and Texas A&M chemical engineering professor Ray Anthony were leaders of the team that developed CSTs in the early 1990s response to a need for materials to remove radioactive contaminants from wastewater. They found that a certain class of synthetic zeolite is more effective in capturing some radioactive elements, like cesium, than other technologies.
They created CSTs: inorganic, molecularly engineered ion exchangers that can be sized specifically for cesium and other elements. When high-level radioactive elements are removed from contaminated water with CSTs, the remaining lower-level radioactive waste can be treated in a more economical and less hazardous way.
UOP worked with Sandia through a Cooperative Research & Development Agreement (CRADA) to produce a commercial-scale manufacturing procedure for the CSTs. "We developed a technology to bind the material into a beaded form so it could be used in ion exchange columns," said Dennis Fennelly, UOP marketing manager.
The company licensed and began commercializing the technology in 1994. It was one of the first licenses issued by Sandia, which had begun its tech transfer program just a year earlier.
Rigali said CST technology was among the Labs' first Laboratory Directed Research and Development (LDRD) commercial product successes. "It was a very early CRADA success as well," he said. "There was program money on our side and there was interest on the commercial side, so the two groups got together and developed the CSTs as a commercial product."
Most read news
Organizations
Other news from the department science
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.